KHN Morning Briefing

Summaries of health policy coverage from major news organizations

full issue

Lupin’s Diabetes Drug Sales Leads Company To Meet Profit Estimates

Also in the news, the health and safety device maker Halma buys a company known for making sensors in an effort to expand its U.S. footprint.

Reuters: Lupin Expects Diabetes Drug Sales To Lift Q4 Profit
Lupin Ltd, India's third-largest drugmaker, reported a quarterly profit that met estimates as strong sales in its local market help offset weakness in the United States, and the company said it expects fourth-quarter earnings to improve. (Siddiqui, 2/5)

Reuters: Halma Buys Healthcare Sensors Maker CenTrak For About $140M
Halma Plc, a health and safety device maker, said it had bought CenTrak Inc, a privately owned maker of sensors, for about $140 million (95.9 million pounds), expanding its footprint in the U.S. healthcare market. Newtown, Pennsylvania-based CenTrak's technology allows for real-time monitoring of patient, staff, medical equipment, and hygiene compliance and temperature conditions. (2/5)

This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.